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PSmoking and Platelet Function
nly Two-Week Smoking Cessation
mproves Platelet Aggregability and
ntraplatelet Redox Imbalance of Long-Term Smokers
irohiko Morita, MD, Hisao Ikeda, MD, PHD, Nobuya Haramaki, MD, PHD,
iroyuki Eguchi, MD, PHD, Tsutomu Imaizumi, MD, PHD, FACC
urume, Japan
OBJECTIVES We investigated whether and how soon smoking cessation ameliorates the smoking-induced
intracellular oxidative stress and platelet aggregability in long-term smokers.
BACKGROUND Smoking is a major risk factor of atherothrombosis. Smoking cessation reduces cardiac events.
However, the underlying mechanisms of the beneficial effects remain to be elucidated.
METHODS Twenty-seven male long-term smokers were divided into two groups. Group A (n 14) quit
smoking for four weeks whereas group B (n 13) resumed smoking two weeks after quitting.
Smoking status was monitored by measurement of urinary cotinine. Using gel-filtered
platelets, agonist (adenosine diphosphate and collagen)-induced platelet aggregation,
platelet-derived nitric oxide (PDNO), intraplatelet nitrotyrosine production, intraplatelet
levels of the reduced form of glutathione (GSH) and its oxidized form (GSSG), and urinary
8-hydroxy-2=-deoxyguanosine (8-OHdG) and urinary 8-iso-prostaglandin F2 (8-iso-
PGF2), as markers of systemic oxidative stress, were measured. The baseline measurements
were similar between the two groups.
RESULTS Smoking cessation quickly reduced agonist-induced platelet aggregations, intraplatelet
nitrotyrosine level, and urinary productions of 8-OHdG and 8-iso-PGF2 by two weeks in
both groups. In group A, they were maintained at the low levels until four weeks, whereas
they were reversed by resmoking in group B; PDNO release and intraplatelet GSH/GSSG
ratio were time-dependently increased by smoking cessation but reversed by resmoking.
CONCLUSIONS The present findings are the first demonstration that only two weeks of smoking cessation can
ameliorate the enhanced platelet aggregability and intraplatelet redox imbalance in long-term
smokers, possibly by decreasing oxidative stress. Our findings may strengthen the motivation
for smokers to quit smoking. (J Am Coll Cardiol 2005;45:589–94) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.061American College of Cardiology Foundation
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apidemiological studies have demonstrated that chronic
moking is a major risk factor for the development of
therosclerosis and thrombosis (1–3). These overwhelming
pidemiological data closely link long-term smoking to
dverse cardiovascular effects. Indeed, previous studies have
hown the enhanced platelet aggregability (4–6) and the
lterations in the clotting cascade in long-term smokers,
uggesting the exaggerated risk of coronary artery throm-
osis (7,8).
Platelets possess the L-arginine–nitric oxide (NO) path-
ay through constitutive NO synthase in humans (9,10).
e have previously shown that long-term smoking impairs
latelet-derived nitric oxide (PDNO) release (6), which acts
s a negative feedback mechanism to inhibit not only
latelet aggregation (11) but also recruitment after aggre-
ation (12). Furthermore, we have recently shown that
mpaired PDNO bioactivity and augmented platelet aggre-
ability in long-term smokers are related to the imbalance of
he intraplatelet redox state, suggesting the smoking-
From the Department of Internal Medicine III, Kurume University School of
edicine, Kurume, Japan.q
Manuscript received August 7, 2004; revised manuscript received September 23,
004, accepted October 20, 2004.nduced oxidative stress for platelet activation (5,6). Thus,
moking-induced platelet-mediated thrombotic mecha-
isms may be involved in the pathophysiology of coronary
rtery disease of long-term smokers. It has been previously
eported that smoking cessation is associated with a reduc-
ion in the risk of cardiovascular disease (13,14). However,
he underlying mechanisms of the beneficial effects remain
nclear. Accordingly, we investigated whether and how
oon smoking cessation ameliorates impaired PDNO bio-
ctivity and augmented platelet aggregability by improving
he imbalance of the intraplatelet redox state. To assess this
ssue, we examined the effects of smoking cessation on
latelet aggregation, PDNO bioactivity, intraplatelet nitro-
yrosine production, the intraplatelet redox state, and sys-
emic oxidative stress.
ETHODS
tudy subjects. The study groups consisted of 27 healthy
ale medical students in our university who smoked at least
5 cigarettes per day for more than 5 years (mean age, 27.4
ears old). They were randomly divided into the two groups
fter baseline measurements (Table 1). Group A (n  14)
uit smoking for 28 days, whereas group B (n  13)
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Smoking Cessation and Intraplatelet Redox Balance February 15, 2005:589–94esumed smoking at day 14 after quitting. We told the
olunteers at the beginning of the study not to change their
ifestyle. Smokers had abstained from smoking for at least
20 min before initiating the protocol to avoid the acute
ffects of smoking on platelet function. Thereafter, blood
ampling was performed at 7, 14, 21, and 28 days, and
rinary sampling was performed at 14 and 28 days after the
tart of the protocol. Smoking status was monitored by
eekly measurements of urinary cotinine in all subjects. The
rotocol was approved by the institutional ethics committee.
ritten informed consent was obtained from all subjects.
reparation of washed platelets. Platelet suspensions were
repared as described previously (4). Briefly, blood (20 ml)
as collected by venipuncture into a plastic tube containing
.15% trisodium citrate. Platelet-rich plasma (PRP) and
latelet-poor plasma (PPP) were prepared according to the
reviously described method (15). The platelets counts were
djusted to 2  105 platelets/l in Tyrode’s solution, the
omposition of which was described previously (4).
easurements of platelet aggregation. We measured
denosine diphosphate (ADP)- and collagen-induced plate-
et aggregations as described previously (5,6). In brief, ADP
5 and 10 mol/l) and collagen (0.2 and 0.5 g/ml) were
dded to the washed platelet suspensions, and light trans-
Abbreviations and Acronyms
ADP  adenosine diphosphate
GSH  reduced form of glutathione
GSSG  oxidized form of glutathione
NO  nitric oxide
PDNO  platelet-derived nitric oxide
PRP  platelet-rich plasma
PPP  platelet-poor plasma
8-iso-PGF2  8-iso-prostaglandin F2
8-OHdG  8-hydroxy-2=-deoxyguanosine
able 1. Baseline Characteristics
Group A
(n  14)
Group B
(n  13)
ge (yrs) 29  8 27  5
ender (male/female) (n) 14/0 13/0
ody mass index (kg/m2) 22  2 22  2
igarettes per days (n) 21  7 23  8
moking period (yrs) 10  5 9  4
ystolic/diastolic blood pressure
(mm Hg)
118  13 115  14
eart rate (beats/min) 71  7 72  9
otal cholesterol (mg/dl) 176  30 175  14
DL cholesterol (mg/dl) 58  10 59  8
DL cholesterol (mg/dl) 100  19 99  13
asting blood glucose (mg/dl) 88  7 88  9
ibrinogen (mg/dl) 202  28 291  47
lasma epinephrine (mg/dl) 38  21 41  20
lasma norepinephrine (pg/dl) 313  72 319  85
rinary cotinine (ng/ml) 1,121  559 1,158  695r
alues are presented as mean  SD. All p  NS.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.ission was monitored by using a platelet aggregometer
MDM Hematracer, MC Medical Co., Tokyo, Japan).
easurements of PDNO. We measured NO by using an
O meter (Model N0-501, Inter Medical Co., Tokyo,
apan) as described previously (4). After the baseline electric
as stabilized, an ADP-induced (50 mol/l) electrical
urrent was recorded at the rate of 20 mm/min, and a
hange in the peak electrical current was considered as an
ndex of the NO release.
easurements of intraplatelet redox status. We mea-
ured intraplatelet GSH (the reduced form of glutathione)
nd GSSG (the oxidized form of glutathione) by high-
erformance liquid chromatography (HPLC) with an elec-
rochemical detection system (ECD-300, Eicom Co.,
yoto, Japan) as previously described (16). The analytical
olumn was a 150  4.6 mm, SC-5 ODS (Eicom Co). For
PLC measurements, PRP and PPP were mixed with
ClO4 (final concentration, 6%), sonicated for 5 s with a
ip sonicator (Model MS-50, Heat System-Ultrasonic Inc.,
armingdale, New York), and centrifuged at 12,000 g for 2
in. The supernatant was then stored at 80°C until
njection into the HPLC column. Intraplatelet GSH/
SSG ratio was calculated as an index of intraplatelet
xidative stress.
etection of intraplatelet nitrotyrosine. We measured
ntraplatelet nitrotyrosine production by using a modified
ethod of a previous study. Immunolabeling was performed
y using a polyclonal antibody to nitrotyrosine as a primary
ntibody and fluoresein isothiocyanate-conjugated goat
nti-rabbit immunoglobulin G (IgG) as a secondary anti-
ody, and then analyzed with the FACScan (Becton-
eckinson, San Diego, California). The results were ex-
ressed as the percent changes in nitrotyrosine-specific
taining of platelets by collagen-induced platelet aggrega-
ion in each group.
easurements of urinary 8-hydroxy-2=-deoxyguanosine
8-OHdG) and 8-iso-prostaglandin PGF2 (8-iso-
GF2). We measured urinary 8-OHdG, an indicator of
NA oxidation (ELISA kit, Japan Institute for the Control
f Aging, Tokyo, Japan), and urinary 8-iso-PGF2, a
roduct of lipid peroxidation (Cayman Chemical Company,
nn Arbor, Michigan), using 24-h urine samples, according
o previously described procedures (17–19).
tatistical analysis. Values are presented as means  SD.
tatistical comparisons between groups were performed by
n unpaired Student t test. Multiple comparisons were
nalyzed by two-way repeated-measures analysis of variance
ith a post-hoc Scheffé’s test. Differences were considered
tatistically significant at p  0.05.
ESULTS
aseline characteristics of the study subjects. The body
ass index distribution of the subjects was similar between
he two groups (Table 1). All subjects had no other major
isk factors including hypercholesterolemia, hypertension,
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February 15, 2005:589–94 Smoking Cessation and Intraplatelet Redox Balancend diabetes mellitus. Furthermore, the two groups did not
iffer in levels of fibrinogen, plasma epinephrine, and
orepinephrine. Urinary cotinine levels were elevated in
oth groups, indicating that they were smokers. The urinary
otinine levels in group A were not detectable after smoking
essation, but those in group B were reversed after resmok-
ng (0 ng/ml at day 14 and 1,310  720 ng/ml at day 28).
latelet aggregations. At baseline, agonist (ADP or
ollagen)-induced platelet aggregations were similar be-
ween the two groups. In group A, agonist-induced platelet
ggregations significantly and time-dependently decreased
hroughout the smoking cessation (Fig. 1). In group B,
gonist-induced platelet aggregations significantly and
ime-dependently decreased until day 14, but those rapidly
eturned to the baseline level by resmoking.
DNO. At baseline, the PDNO level was similar between
he two groups. In group A, PDNO significantly and
ime-dependently increased throughout the smoking cessa-
ion (Fig. 2). In group B, PDNO significantly and time-
ependently increased by day 14, but it quickly returned to
he baseline level by resmoking.
ntraplatelet GSH/GSSG ratio. At baseline, the in-
raplatelet GSH/GSSG ratio was similar between the two
roups. In group A, the ratio significantly and time-
ependently increased throughout the smoking cessation
igure 1. Time course of platelet aggregations in subjects who quit smoking
ote that platelet aggregations were time-dependently decreased after
ggregations returned to the baseline values by resmoking. *p  0.01 vs. da
. ADP  adenosine diphosphate.Fig. 3). In group B, the ratio significantly and time-
v
iependently increased by day 14 after smoking cessation,
ut it quickly returned to the baseline level by resmoking.
ntraplatelet nitrotyrosine. At baseline, the intraplatelet
itrotyrosine level was similar between the two groups. In
roup A, it significantly and time-dependently decreased
hroughout the smoking cessation (Fig. 4). In group B, it
ignificantly and time-dependently decreased by day 14 after
moking cessation, but it quickly returned to the baseline
evel by resmoking.
p A, open bars) and subjects who resumed smoking (group B, solid bars).
ng cessation; however, in the subjects who resumed smoking, platelet
group A; †p  0.05 vs. day 0 in group B; ‡p  0.05 vs. day 14 in group
igure 2. Time course of platelet-derived nitric oxide (PDNO) in subjects
ho quit smoking (group A, open bars) and subjects who resumed
moking (group B, solid bars). Note that PDNO was time-dependently
ncreased after smoking cessation; however, in the subjects who resumed
moking, PDNO returned to the baseline values by resmoking. *p  0.01(grou
smokis. day 0 in group A; †p  0.05 vs. day 0 in group B; ‡p  0.05 vs. day 14
n group B.
M
u
b
t
t
b
t
D
H
c
a
6
s
a
b
s
m
s
t
A
e
a
a
f
s
s
a
d
n
t
l
t
g
d
b
F
o
A
N
s
i
*
v
F
s
B
d
s
r
B
F
8
A
N
c
r
A
8
d
592 Morita et al. JACC Vol. 45, No. 4, 2005
Smoking Cessation and Intraplatelet Redox Balance February 15, 2005:589–94arkers of systemic oxidative stress. At baseline, the
rinary levels of 8-OHdG and 8-iso- PGF2 were similar
etween the two groups. In group A, they significantly and
ime-dependently decreased throughout the smoking cessa-
ion (Fig. 5). In group B, they time-dependently decreased
y day 14 after smoking cessation, but they quickly returned
o the baseline levels by resmoking.
ISCUSSION
ow soon is platelet aggregability reversible after smoking
essation? It is well known that platelet aggregability is more
ugmented in long-term smokers than in nonsmokers (4–
). Although the importance of primary prevention of
moking is well recognized, quitting smoking is not so
ppreciated; long-term smokers tend to underestimate the
enefit of quitting smoking and are pessimistic to quit
moking. The reason for this underestimation and pessi-
ism may derive from the fact that many long-term
igure 3. Time course of intraplatelet reduced form of glutathione (GSH)/
xidized form of glutathione (GSSG) in subjects who quit smoking (group
, open bars) and subjects who resumed smoking (group B, solid bars).
ote that intraplatelet GSH/GSSG was time-dependently increased after
moking cessation; however, in the subjects who resumed smoking,
ntraplatelet GSH/GSSG returned to the baseline values by resmoking.
p  0.01 vs. day 0 in group A; †p  0.05 vs. day 0 in group B; ‡p  0.05
s. day 14 in group B.
igure 4. Time course of intraplatelet nitrotyrosine in subjects who quit
moking (group A, open bars) and subjects who resumed smoking (group
, solid bars). Note that intraplatelet nitrotyrosine was time-dependently
ecreased after smoking cessation; however, in the subjects who resumed
moking, intraplatelet nitrotyrosine returned to the baseline values byb
esmoking. *p  0.01 vs. day 0 in group A; †p  0.05 vs. day 0 in group
; ‡p  0.05 vs. day 14 in group B.mokers have established atherosclerosis and from the fact
hat they cannot see the immediate benefits by themselves.
s far as we know, there has been only one study that
xamined acute effects of smoking cessation on platelet
ggregability (20). They reported that augmented platelet
ggregability in long-term smokers was not reversible in
our to six weeks. However, their study enrolled very few
ubjects, and, moreover, they did not monitor smoking
tatus by measuring blood or urinary nicotine levels. As
pparent from the study design, our study was carefully
esigned with a monitor of smoking status by measuring
icotine (cotinine) levels. Our results showed that only
wo-week smoking cessation reversed the augmented plate-
et aggregability in long-term smokers. In the present study,
he baseline characteristics did not differ between the two
roups. Furthermore, the urinary cotinine levels were not
etectable after smoking cessation, and they returned to the
aseline value after resmoking. Thus, the platelet aggrega-
igure 5. Time course of markers of systemic oxidative stress ([A]: urinary
-OHdG; [B]: urinary 8-iso-PGF2) in subjects who quit smoking (group
, open bars) and subjects who resumed smoking (group B, solid bars).
ote that those markers were time-dependently decreased after smoking
essation; however, in the subjects who resumed smoking, those markers
eturned to the baseline values by resmoking. *p  0.01 vs. day 0 in group
; †p  0.05 vs. day 0 in group B; ‡p  0.05 vs. day 14 in group B.
-iso-PGF2  8-iso-prostaglandin F2; 8-OHdG  8-hydroxy-2=-
eoxyguanosine.ility was exclusively related to the smoking status. The
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February 15, 2005:589–94 Smoking Cessation and Intraplatelet Redox Balanceesults of our study may be in agreement with those that
xamined acute effects of smoking cessation on endothelial
unction (21) in which they showed that only one day of
moking cessation reversed endothelial dysfunction of hu-
an veins in long-term smokers. Although we did not
xamine platelet aggregability one day after smoking cessa-
ion, platelet aggregability was not fully reversed until day
4. It is not clear why smoking cessation reversed endothe-
ial dysfunction within one day after smoking cessation
hereas it took two weeks for platelet dysfunction to
ecover. Anyway, our results may provide some motivation
or smokers to quit smoking.
echanisms of rapidly reversed platelet aggregability in
ong-term smokers. In order to examine the mechanisms
y which platelet aggregability was rapidly reversed by
moking cessation, we measured PDNO and oxidative
tress. Platelets possess the L-arginine–NO pathway
hrough constitutive NO synthase in humans (10,22);
DNO acts as a negative feedback mechanism for platelet
ggregation (11). In our previous studies (4,6), we have
hown that PDNO was lower in long-term smokers than in
onsmokers and that impaired PDNO bioactivity is respon-
ible for the augmented platelet aggregability in long-term
mokers. Thus, in this study we measured PDNO and
latelet aggregability at the same time after smoking cessa-
ion. Our results indicate that the changes in PDNO and
latelet aggregability were parallel during smoking cessation
nd resmoking. Accordingly, the present observations sug-
est that the improved platelet aggregability is exclusively
elated to augmented PDNO. To further address the
echanism for augmented PDNO, we measured intraplate-
et peroxynitrite production, the reaction product of super-
xide anion and NO (23). Intraplatelet nitrotyrosine was
ignificantly decreased after smoking cessation, whereas it
as significantly increased after resmoking. Thus, our find-
ngs may indicate that the bioactivity of NO is impaired by
xidative stress in long-term smokers and is rapidly reversed
fter smoking cessation, resulting in improved platelet
ggregability.
As previously discussed, it is likely that oxidative stress
mpairs bioactivity of PDNO, which is rapidly improved by
moking cessation. In order to further address this issue, we
easured urinary levels of 8-OHdG, an indicator of DNA
xidation and 8-iso-PGF2, a product of lipid peroxidation,
s markers of systemic oxidative stress. Although these two
arkers have been reported to be elevated in chronic
mokers (24–26), we, for the first time, show that these
arkers were decreased after smoking cessation and were
ncreased after resmoking. We also measured intraplatelet
evels of GSH and GSSG and obtained the ratio of
SH/GSSG for a marker of intraplatelet oxidative stress.
n our previous study, we reported that GSH/GSSG ratio
as lower in long-term smokers than in nonsmokers (5).
ntracellular GSH serves as a free radical scavenger (27,28).
oreover, GSH not only regulates the intracellular redoxtate but also modulates the action and metabolism of NO t29,30). Indeed, it has been shown in cultured endothelial
ells that depletion of GSH decreases synthesis of NO (31)
nd that reduced thiol enhances NO activity (32). These
ndings indicate that intracellular GSH plays an important
ole in modulating the action and metabolism of NO. In our
ecent study, we reported that smoking-induced oxidative
tress is associated with decreased intraplatelet GSH levels,
esulting in an imbalance of the intraplatelet redox state in
ong-term smokers (5,6). However, the effects of smoking
essation on the intraplatelet redox state in long-term
mokers were unknown previously. In this study, we mea-
ured not only GSH but also its oxidized form, GSSG. The
ehavior of intraplatelet GSH/GSSG ratio was similar to
hat of peroxynitrite and PDNO during smoking cessation
nd resmoking. In our previous studies using NG-nitro-L-
rginine methylester, an inhibitor of NO synthase, or
,5-dihydroxy-1,3-benzene disulfonic acid, an intracellular
cavenger of superoxide anion, we confirmed that in-
raplatelet nitrotyrosine was really a “footprint” of peroxyni-
rite, resulting from the interaction between NO and
uperoxide anion (6,33). These findings indicate that smok-
ng cessation rapidly improves the imbalance of the in-
raplatelet redox state in long-term smokers. Taken to-
ether, present findings indicate that smoking cessation
apidly improves not only the systemic oxidative stress but
lso the imbalance of intracellular redox state, resulting in
mprovements of bioactivity of PDNO and platelet aggre-
ability in long-term smokers. Finally, it is interesting to
ote that the changes in intraplatelet markers of redox state
fter smoking cessation were greater than those of systemic
xidative stress. Thus, intraplatelet GSH/GSSG ratio and
itrotyrosine may be more sensitive and useful markers of
xidative stress than 8-OHdG and 8-iso-PGF2 in the
lood.
The present study has some study limitations. In this
tudy, because we studied young, healthy individuals, cau-
ion is warranted when extrapolating present findings to
atients with atherosclerosis or to those with multiple
ardiovascular risk factors.
In conclusion, the present study, to the best of our
nowledge, provides the first demonstration that only two
eeks of smoking cessation ameliorates the enhanced plate-
et aggregability and intraplatelet redox imbalance through
mprovement of oxidative stress. Our findings may contrib-
te to the understanding of the pathophysiological link of
moking cessation to beneficial cardiovascular effects. Fur-
hermore, present findings may strengthen the motivation
or smokers, especially patients with atherothrombosis, to
uit smoking.
cknowledgment
he authors are grateful to Kimiko Kimura for her excellent
echnical assistance.
R
m
M
i
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
594 Morita et al. JACC Vol. 45, No. 4, 2005
Smoking Cessation and Intraplatelet Redox Balance February 15, 2005:589–94eprint requests and correspondence: Dr. Hisao Ikeda, Depart-
ent of Internal Medicine III, Kurume University School of
edicine, 67 Asahi-machi, Kurume, 830-0011, Japan. E-mail:
keda_hisao@kurume-u.ac.jp.
EFERENCES
1. Strong JP, Richards ML. Cigarette smoking and atherosclerosis in
autopsied men. Atherosclerosis 1976;23:451–76.
2. The Pooling Project Research Group. Relationship of blood pressure,
serum cholesterol, smoking habit, relative weight and ECG abnormal-
ities to incidence of major coronary events: final report of the pooling
project. J Chronic Dis 1978;31:201–306.
3. Jonas M, Oates J, Ockene J, Hennekens C. Statement on smoking and
cardiovascular disease for health care professionals. American Heart
Association. Circulation 1992;86:1664–9.
4. Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Long-term
smoking impairs platelet-derived nitric oxide release. Circulation
1996;94:3109–14.
5. Haramaki N, Ikeda H, Takajo Y, et al. Long-term smoking causes
nitroglycerin resistance in platelets by depletion of intraplatelet gluta-
thione. Arterioscler Thromb Vasc Biol 2001;21:1852–6.
6. Takajo Y, Ikeda H, Haramaki N, Murohara T, Imaizumi T. Aug-
mented oxidative stress of platelets in chronic smokers. Mechanisms of
impaired platelet-derived nitric oxide bioactivity and augmented plate-
let aggregability. J Am Coll Cardiol 2001;38:1320–7.
7. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and
other characteristics on clotting factors and the risk of ischaemic heart
disease. Lancet 1987;2:986–8.
8. Fitzgerald GA, Oates JA, Nowak J. Cigarette smoking and hemostatic
function. Am Heart J 1988;115:267–71.
9. Radomski M, Moncada S. An improved method for washing of
human platelets with prostacyclin. Thromb Res 1983;30:383–9.
0. Sase K, Michel T. Expression of constitutive endothelial nitric oxide
synthase in human blood platelets. Life Sci 1995;57:2049–55.
1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, patho-
physiology, and pharmacology. Pharmacol Rev 1991;43:109–42.
2. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF, Jr., Vita JA.
Impaired platelet production of nitric oxide predicts presence of acute
coronary syndromes. Circulation 1998;98:1481–6.
3. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of
myocardial infarction. N Engl J Med 1992;326:1406–16.
4. Lightwood JM, Glantz SA. Short-term economic and health benefits
of smoking cessation: myocardial infarction and stroke. Circulation
1997;96:1089–96.
5. Kuwano K, Ikeda H, Oda T, et al. Xanthine oxidase mediates cyclic
flow variations in a canine model of coronary arterial thrombosis. Am J
Physiol 1996;270:H1993–9.
6. Honegger CG, Langemann H, Krenger W, Kempf A. Liquid chro-
matographic determination of common water-soluble antioxidants in
biological samples. J Chromatogr 1989;487:463–8.
7. Erhola M, Toyokuni S, Okada K, et al. Biomarker evidence of DNA
oxidation in lung cancer patients: association of urinary 8-hydroxy-2=-deoxyguanosine excretion with radiotherapy, chemotherapy, and
response to treatment. FEBS Lett 1997;409:287–91.
8. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohisto-
chemical determination of 8-hydroxy-2=-deoxyguanosine by a mono-
clonal antibody N45.1: its application to ferric nitrilotriacetate-
induced renal carcinogenesis model. Lab Invest 1997;76:365–74.
9. Proudfoot J, Barden A, Mori TA, et al. Measurement of urinary
F2-isoprostanes as markers of in vivo lipid peroxidation—a comparison
of enzyme immunoassay with gas chromatography/mass spectrometry.
Anal Biochem 1999;272:209–15.
0. Chiang VL, Castleden WM, Leahy MF. Detection of reversible
platelet aggregates in the blood of smokers and ex-smokers with
peripheral vascular disease. Med J Aust 1992;156:601–3.
1. Moreno H, Chalon S, Urae A, et al. Endothelial dysfunction in human
hand veins is rapidly reversible after smoking cessation. Am J Physiol
Heart Circ Physiol 1998;275:H1040–5.
2. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide
pathway present in human platelets regulates aggregation. Proc Natl
Acad Sci USA 1990;87:5193–7.
3. Williams MS, Noguchi S, Henkart PA, Osawa Y. Nitric oxide
synthase plays a signaling role in TCR-triggered apoptotic death.
J Immunol 1998;161:6526–31.
4. Smith CJ, Fischer TH, Heavner DL, et al. Urinary thromboxane,
prostacyclin, cortisol, and 8-hydroxy-2=-deoxyguanosine in nonsmok-
ers exposed and not exposed to environmental tobacco smoke. Toxicol
Sci 2001;59:316–23.
5. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating
products of lipid peroxidation (F2-isoprostanes) in smokers—smoking
as a cause of oxidative damage. N Engl J Med 1995;332:1198–203.
6. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of
oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;
94:19–25.
7. Meister A. Glutathione-ascorbic acid antioxidant system in animals.
J Biol Chem 1994;269:9397–400.
8. Haramaki N, Stewart DB, Aggarwal S, Ikeda H, Reznick AZ, Packer
L. Networking antioxidants in the isolated rat heart are selectively
depleted by ischemia-reperfusion. Free Radical Biol Med 1998;25:
329–39.
9. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its
redox-activated forms. Science 1992;258:1898–902.
0. Keaney JF, Simon DI, Stamler JS, et al. NO forms an adduct with
serum albumin that has endothelium-derived relaxing factor-like
properties. J Clin Invest 1993;91:1582–9.
1. Murphy ME, Piper HM, Watanabe H, Sies H. Nitric oxide produc-
tion by cultured aortic endothelial cells in response to thiol depletion
and replenishment. J Biol Chem 1991;266:19378–83.
2. Stamler JS, Mendelsohn M, Amarante P, et al. N-acetylcysteine
potentiates platelet inhibition by endothelium-derived relaxing factor.
Circ Res 1989;65:789–95.
3. Kanaya S, Ikeda H, Haramaki N, Murohara T, Imaizumi T. In-
traplatelet tetrahydrobiopterin plays an important role in regulating
canine coronary arterial thrombosis by modulating intraplatelet nitric
oxide and superoxide generation. Circulation 2001;104:2478–84.
